checkpoint inhibitors
-
First-line immunotherapy reduced progression hazard 39% in MSI-H metastatic colorectal cancer
A meta-analysis of two randomised phase III trials found longer progression-free and overall survival with first-line checkpoint-inhibitor therapy than chemotherapy in MSI-H/dMMR metastatic colorectal cancer. The evidence is…
-
Severe immune toxicity linked to 48.6% response in MSI-H cancers
In this 1,175-patient retrospective study, people who developed severe immune-related side effects had a higher recorded response rate to immunotherapy. The association is hypothesis-generating, not proof that toxicity…